期刊文献+

丙泊酚复合瑞芬太尼靶控输注麻醉对宫颈癌患者血压、心率及预后的影响 被引量:6

Effects of propofol combined with remifentanil target-controlled infusion anesthesia on blood pressure, heart rate and prognosis of patients with cervical cancer
下载PDF
导出
摘要 目的探讨丙泊酚复合瑞芬太尼靶控输注麻醉对宫颈癌患者血压、心率及预后的影响。方法选取2015年5月至2018年12月于我院行宫颈癌手术的79例患者为研究对象,按随机数字表法将其分为参照组(39例)和观察组(40例)。参照组采用丙泊酚复合瑞芬太尼持续静脉输注麻醉,观察组采用丙泊酚复合瑞芬太尼靶控输注麻醉。比较两组患者进入手术室即刻(T0)、插管即刻(T1)、手术开始后3 min(T2)、术毕即刻(T3)的收缩压(SBP)、舒张压(DBP)、心率(HR)、拔管后不同时间的镇静情况、拔管时间、苏醒时间及不良反应发生情况。结果观察组T1、T2、T3时刻的SBP、DBP、HR与T0时刻比较,差异不显著(P>0.05);拔管后5、15 min,观察组OAAS评分显著高于参照组(P<0.05);观察组的拔管时间及苏醒时间显著短于参照组(P<0.05)。观察组苏醒期躁动1例(2.50%),参照组苏醒期躁动3例(7.69%),组间比较,差异不显著(P>0.05)。结论宫颈癌患者手术开始后3 min予以丙泊酚复合瑞芬太尼靶控输注麻醉可减轻对血压、心率的影响,且术后苏醒迅速,不良反应少。 Objective To investigate the effects of propofol combined with remifentanil target-controlled infusion anesthesia on blood pressure, heart rate and prognosis of patients with cervical cancer. Methods Seventy-nine patients undergoing cervical cancer surgery in our hospital from May 2015 to December 2018 were selected as the study objects and divided into reference group (39 cases) and observation group (40 cases) according to the random number table method. The reference group received continuous intravenous anesthesia with propofol combined with remifentanil, and the observation group received targeted-controlled anesthesia with propofol combined with remifentanil. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) of immediately after entering the operating room (T0), immediately intubation (T1), 3 min after the operation starting (T2), and immediately after the operation (T3), sedation at different time after extubation, extubation time, recovery time and adverse reactions were compared between the two groups. Results There were no significant differences in SBP, DBP, HR of the observation group between T1, T2, T3 and T0 (P>0.05). At 5 and 15 min after extubation, the OAAS score in the observation group was significantly higher than that in the reference group (P<0.05). The time of extubation and recovery in the observation group were significantly shorter than those in the reference group (P<0.05). There was 1 case (2.50%) of restlessness during recovery in the observation group and 3 cases (7.69%) in the reference group, there was no significant difference between the two groups(P>0.05). Conclusion Propofol combined with remifentanil target-controlled infusion anesthesia at 3 min after the operation starting for patients with cervical cancer can reduce the impact on blood pressure and HR, with faster postoperative recovery and fewer adverse reactions.
作者 杨敏 康超 YANG Min;KANG Chao(Anesthesiology Department, Northwest Women's and Children's Hospital, Xi'an 710061, China)
出处 《临床医学研究与实践》 2019年第29期93-95,共3页 Clinical Research and Practice
关键词 丙泊酚 瑞芬太尼 靶控输注 麻醉 宫颈癌 propofol remifentanil target-controlled infusion anesthesia cervical cancer
  • 相关文献

参考文献8

二级参考文献67

  • 1郭絮飞.姜黄素对C-33A人子宫颈癌细胞株增殖的影响及其相关机制[J].中国老年学杂志,2014,34(11):3082-3083. 被引量:2
  • 2邹建平,黄燕娟,冉雪莲,黄国勇.瑞芬太尼复合异丙酚在妇科腹腔镜手术麻醉中的应用(附20例分析)[J].广西医科大学学报,2005,22(5):773-774. 被引量:8
  • 3张熙哲,吴新民.异丙酚靶控输注时瑞芬太尼抑制气管插管反应的半数有效血浆浓度[J].中华麻醉学杂志,2006,26(3):204-206. 被引量:45
  • 4Marana E, Colicci S, Meo F, et al. Neuroendocrine stress re- sponse in gynecological laparoscopy: TIVA with propfol versus sevoflurane anesthesia [J]. J Clin Anesth, 2010,22 (4) : 250-255.
  • 5Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN3 + risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines [J]. J Low Genit Tract Dis, 2013, 17 (5 Suppl 1) : $28-35. DOI: 10.1097/ LGT.0b013e318285423c.
  • 6Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer [J]. CA Cancer J Clin, 2012, 62 (3) .. 147-172. DOI : 10.3322/caac.21139.
  • 7Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors [ J ] Obstet Gynecol, 2013,121(4) :829-846. DOI: 10.1097/AOG. 0b013e3182883a34.
  • 8Gage JC, Katki HA, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus- negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management [J]. Cancer Cytopathol, 2014, 122 (11) : 842-850. DOI: 10.1002/ cncv.21463.
  • 9Zhao FH, Lin M J, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China[J]. Lancet Oncol, 2010, 11 (12) : 1160-1171. DOI: 10.1016/S1470-2045( 10)70256-4.
  • 10Schiffman M, Vaughan LM, Raine-Bennett TR, et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results [J]. Gynecol Oncol, 2015, 138 (3): 573-578. DOI: 10.1016/j.ygyno.2015.06.040.

共引文献164

同被引文献69

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部